Treatment adherence is crucial for curing patients with active tuberculosis (TB). Adverse effects of TB treatment significantly contribute to non-adherence, which has its consequences for TB control. Antituberculosis druginduced hepatotoxicity (ATDH) is a serious adverse effect, which causes substantial morbidity and mortality, complicating TB treatment. The incidence of ATDH has been variably reported as between 2% and 11% (Dossing et al. 1996; Schaberg et al. 1996; Yee et al. 2003; FernandezVillar et al. 2004 ). This rate depends on the investigators' definition of hepatotoxicity as well as the population studied. Most studies on ATDH are performed in Europe, Southeast Asia and northern America. Data on ATDH in sub-Saharan Africa are limited. This is probably due to the fact that transaminases are not measured routinely and hepatotoxicity is often diagnosed clinically by the occurrence of jaundice.
We report the proportion of antituberculosis druginduced hepatotoxicity cases observed in a randomised clinical trial on cotrimoxazole (CTX) prophylaxis in 579 Malawian HIV-positive adult tuberculosis patients. They were treated for smear-positive pulmonary TB with an 8-month regimen of 1SHRZ/1S 3 H 3 R 3 Z 3 /6HE (see Box 1 for explanation) plus daily CTX at a dose of 480 or 960 mg (Boeree et al. 2005) . None received antiretroviral treatment. They were followed-up every 4 weeks until the end of TB treatment and aminotransferase levels [aspartate aminotransferase (ASAT) and alanine aminotranferase (ALAT)] were measured at enrolment and at months 2, 5 and 8.
During TB treatment, five patients (1.3%) developed grade 2 hepatotoxicity and three patients (0.9%) developed grade 3 hepatotoxicity according to WHO definitions (WHO 1992) . No grade 4 hepatotoxicity was observed in this cohort. Table 1 shows the number of patients with hepatotoxicity at different time points during the study. Patients with grade 1 toxicity were still at risk for toxicity on subsequent measurements.
In this study, ALAT >50 u/l at inclusion and male gender were associated independently with ATDH (Table 2 ). In multivariate analysis, both ALAT >50 u/l at inclusion and male gender tend to be associated with ATDH [adjusted hazard ratios 2.18 (95%CI 0.93-5.07) and 1.58 (95%CI 0.99-2.53) respectively], although at borderline statistical significance. Whether hepatotoxicity was related to alcohol use, HIV infection or concomitant use of other hepatotoxic drugs cannot be concluded from our data. Due to the small numbers, grade 1 toxicity was included in these analyses.
Eighty-five patients (14.7%) died during TB treatment, 44 (7.6%) were lost to follow-up and the trial was stopped in 13 patients (2.2%) upon their request (Figure 1 ). Most deaths were because of TB (n ¼ 22), diarrhoea (n ¼ 19) and meningitis (n ¼ 11); the other causes are summarised in the original paper of Boeree et al. (2005) .
Patients who died or were withdrawn from the trial were more likely to have an ALAT level of >50 u/l at inclusion (9.3%) than patients who remained followed-up until the end of treatment [2.9% (P ¼ 0.02)]. Therefore, these patients were possibly more at risk for ATDH, which could give an underestimation of ATDH in our trial (FernandezVillar et al. 2004) .
The inclusion criteria for the trial are summarised in the original paper. The most relevant inclusion criterion in our study is HIV infection, as this is a risk factor for ATDH (Yee et al. 2003) . Four patients were excluded because of 'jaundice or liver problems'. Regarding the low number, we did not expect this to affect the generalisability of our findings. A total of 80 patients were ineligible according to the exclusion criteria, mostly because of having received TB drugs for more than 8 days. We assume that these criteria were not related to (risk factors for) ATDH.
The low proportion of ATDH in our trial is consistent with the previous studies in sub-Saharan Africa. In a study in former Zaire, TB drugs (2HRZE/4HR) were well tolerated among 446 TB patients. No hepatitis was reported, but increased transaminase-levels were occasionally seen (Perriens et al. 1995) . In a Ugandan study, only two of 265 HIV-infected subjects (1%) developed hepatotoxicity during treatment of pulmonary TB (2HRZE/6HR) (Johnson et al. 2000) . The same group reported that hepatitis and transaminase elevations did occur during preventive TB treatment in HIV-positive patients and that 0.8% had transaminase levels >135 u/l (Whalen et al. 1997) .
These reports suggest that the incidence of ATDH in adults is low in sub-Saharan Africa. This is unexpected, because risk factors such as HIV or hepatitis B and C infection are highly prevalent in this region. There are several possible reasons for this apparently low incidence of ATDH. First, the available studies were not designed to detect ATDH. Cases of mild or transient hepatotoxicity The regular-size number refers to the number of months this regimen is used, the subscript number refers to how many times per week a drug is taken. For example: 1SHRZ/ 1S 3 H 3 R 3 Z 3 /6HE ¼ one month of daily streptomycin, isoniazid, rifampin and pyrazinamide, followed by 1 month of the same four drugs three times a week, followed by 6 months of daily isoniazid and ethambutol. Grade 1 (mild): <2.5 · the upper limit of normal (ULN) (ALAT 51-125 U/l). Grade 2 (mild): 2.6-5 · the ULN (ALAT 126-250 U/l). Grade 3 (moderate): 5-10 · the ULN (ALAT 251-500 U/l). Grade 4 (severe): >10 · the ULN (ALAT >500 U/l). may have been missed. In our study, liver function was monitored only four times during TB treatment. Consequently, the incidence of mild ATDH may be underestimated. However, as serious hepatotoxicity would have most probably been detected at the monthly follow-up visits, we do not consider this possible underestimation clinically relevant. Second, patients who were withdrawn from the trial were probably at higher risk of ATDH than patients who remained in the study until the end of treatment. This could result in an underestimation of hepatotoxicity in our trial. Third, there is some evidence that absorption of TB drugs in adults with HIV/AIDS is worse compared with non-HIV-infected patients (Peloquin et al. 1996) . Although HIV infection is a risk factor for ATDH, this could explain why ATDH is seen less frequently in our HIV-infected population. Possibly, immunosuppresion in patients with advanced AIDS results in fewer side effects during TB treatment. Fourth, ethnic variation causes differences in susceptibility for drug toxicity. Phenotypic variation in human drug metabolism can be attributed to polymorphisms in genes encoding drug-metabolising enzymes. Such polymorphisms may alter enzyme activity and could subsequently increase formation of reactive metabolites (Wilkinson 2005) . In the case of isoniazid, toxic metabolites are responsible for its toxicity. Possibly, genetic polymorphisms in drug metabolising enzymes explain the low incidence of ATDH in subSaharan populations. On the other hand, in our trial all patients were HIV-positive and were on CTX prophylaxis during TB treatment. Because HIV is a risk factor for ATDH, a higher rate of ATDH would have been expected (Yee et al. 2003) . Cotrimoxazole can be hepatotoxic, especially in patients with AIDS (Kovacs et al. 1984) . Therefore, the real incidence of ATDH in patients without concomitant CTX may even be lower. These findings are an incentive to study ATDH in subSaharan Africa. Because of the HIV epidemic, TB rates are increasing in this region. Furthermore, HIV not only increases the burden of tuberculosis in Africa, but also complicates its therapy. Drug interactions and overlapping toxicities are often seen during combined HIV/TB treatment, and drug toxicity has been implicated as a major cause of treatment interruption (Dean et al. 2002; Kwara et al. 2005) . Currently antiretroviral drugs are being introduced on a large scale in sub-Saharan Africa. Our findings are encouraging in that hepatotoxicity due to combined HIV/TB treatment may occur less frequently than expected. However, more studies are needed on hepatotoxicity of combined treatment, in particular, in relation to the degree of immunosuppression as TB can occur at any CD4 level. In addition, more research on the incidence and risk factors for ATDH in Africans may help to prevent serious hepatotoxicity during TB and combined HIV/TB treatment. The prevention of side effects increases treatment adherence and treatment success rates. This will eventually contribute to better TB and HIV control.
Randomized patients n = 579
Between 0-2 months 34 patients died 19 patients lost to follow-up Patients followed after the end of TB treatment n = 437/579 (75.5%)
Between 2-5 months 32 patients died 15 patients lost to follow-up one patient decided to stop Between 5-8 months 19 patients died 10 patients lost to follow-up 12 patients decided to stop 
